Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review

J Hematol Oncol. 2018 Dec 20;11(1):140. doi: 10.1186/s13045-018-0687-0.

Abstract

Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non-anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL.

Keywords: Chemoradiotherapy; Extranodal NK/T cell lymphoma; Localized disease.

Publication types

  • Systematic Review

MeSH terms

  • Chemoradiotherapy / methods*
  • Humans
  • Lymphoma, Extranodal NK-T-Cell / pathology*
  • Nose Neoplasms / drug therapy*
  • Treatment Outcome